Citations

Clear

6274 citation(s) found for "To, Andrew".

Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance)
Labadie, Julia , Hua, Xinwei , Harrison, Tabitha A. , Banbury, Barbara L. , Huyghe, Jeroen R. , Sun, Wei , Shi, Qian , Yothers, Greg , Sinicrope, Frank A. , Goldberg, Richard M. , George, Thomas J. , Phipps, Amanda I. , Peters, Ulrike , Sinicrope, Frank A , Goldberg, Richard M , George, Thomas J , Cohen, Stacey A , Sun, Wei , Harrison, Tabitha A , Shi, Qian , Yothers, Greg , Alberts, Steven R. , Penney, Kathryn , Cohen, Stacey A. , Chan, Andrew T. , Newcomb, Polly A.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 17, 2020 | Volume: 30 | Issue: 2 | Pages: 404-411

10.1158/1055-9965.epi-20-1274 | PMID 33203692 Get It

Abstract Background: Cetuximab, an EGFR inhibitor used to treat multiple cancer types, including colon cancer, causes severe skin toxicity in 5%–20% of patients, leading to decreased quality of life and treatment delays. Our understanding of which patients have an increased risk of severe toxicities is limited. We conducted a genome-wide association study to identify germline variants predictive of cetuximab-induced severe skin toxicity. Methods: Our study included 1,209 patients with stage III colon cancer randomized to receive cetuximab plus 5-fluorouracil and oxaliplatin as part of the NCCTG N0147 (Alliance) clinical trial. Skin toxicity outcomes were collected using the Common Toxicity Criteria for Adverse Events version 3.0. We performed genotyping, evaluating approximately 10 million genetic variants. We used logistic regression to evaluate the association of each genetic variant and severe (grade ≥ 3) skin toxicity, adjusting for age, sex, and genetic ancestry. Genome-wide significance was defined as P < 5 × 10−8. Results: Participants were predominantly middle-aged white men; 20% (n = 243) experienced severe skin toxicity. Two genetic variants in the retinoic acid receptor alpha (RARA) gene were significantly associated with severe skin toxicity [OR, 3.93; 95% confidence interval (CI), 2.47–6.25; P < 7.8 × 10−9]. Functional annotations indicate these variants are in the RARA promoter. Additional significantly associated variants were identified in chromosome 2 intergenic regions. Conclusions: Identified variants could represent a potential target for risk stratification of patients with colon cancer receiving cetuximab. Impact: Retinoids have shown promise in the treatment of cetuximab-induced skin toxicity, so follow-up work could evaluate whether individuals with the RARA variant would benefit from retinoid therapy.
COVID-19–Associated Nonocclusive Fibrin Microthrombi in the Heart
Bois, Melanie C. , Boire, Nicholas, Layman, Andrew J. , Aubry, Marie-Christine, Alexander, Mariam P., Roden, Anja C. , Hagen, Catherine E. , Quinton, Reade A. , Majumdar, Ramanath, Jenkins, Sarah M. , Kipp, Benjamin R. , Lin, Peter T. , Maleszewski, Joseph J. , Boire, Nicholas A, Hagen, Catherine E , Layman, Andrew J. , Larsen, Christopher Patrick , Erben, Young

Mayo Clinic

Circulation | November 16, 2020 | Volume: 143 | Issue: 3 | Pages: 230-243

10.1161/circulationaha.120.050754 | PMID 33197204 Get It

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its resultant clinical presentation, coronavirus disease 2019 (COVID-19), is an emergent cause of mortality worldwide. Cardiac complications secondary to this infection are common; however, the underlying mechanisms of such remain unclear. A detailed cardiac evaluation of a series of individuals with COVID-19 undergoing postmortem evaluation is provided, with 4 aims: (1) describe the pathological spectrum of the myocardium; (2) compare with an alternate viral illness; (3) investigate angiotensin-converting enzyme 2 expression; and (4) provide the first description of the cardiac findings in patients with cleared infection. Methods: Study cases were identified from institutional files and included COVID-19 (n=15: 12 active, 3 cleared), influenza A/B (n=6), and nonvirally mediated deaths (n=6). Salient information was abstracted from the medical record. Light microscopic findings were recorded. An angiotensin-converting enzyme 2 immunohistochemical H-score was compared across cases. Viral detection encompassed SARS-CoV-2 immunohistochemistry, ultrastructural examination, and droplet digital polymerase chain reaction. Results: Male sex was more common in the COVID-19 group ( P =0.05). Nonocclusive fibrin microthrombi (without ischemic injury) were identified in 16 cases (12 COVID-19, 2 influenza, and 2 controls) and were more common in the active COVID-19 cohort ( P =0.006). Four active COVID-19 cases showed focal myocarditis, whereas 1 case of cleared COVID-19 showed extensive disease. Arteriolar angiotensin-converting enzyme 2 endothelial expression was lower in COVID-19 cases than in controls ( P =0.004). Angiotensin-converting enzyme 2 myocardial expression did not differ by disease category, sex, age, or number of patient comorbidities ( P =0.69, P =1.00, P =0.46, P =0.65, respectively). SARS-CoV-2 immunohistochemistry showed nonspecific staining, whereas ultrastructural examination and droplet digital polymerase chain reaction were negative for viral presence. Four patients (26.7%) with COVID-19 had underlying cardiac amyloidosis. Cases with cleared infection had variable presentations. Conclusions: This detailed histopathologic, immunohistochemical, ultrastructural, and molecular cardiac series showed no definitive evidence of direct myocardial infection. COVID-19 cases frequently have cardiac fibrin microthrombi, without universal acute ischemic injury. Moreover, myocarditis is present in 33.3% of patients with active and cleared COVID-19 but is usually limited in extent. Histological features of resolved infection are variable. Cardiac amyloidosis may be an additional risk factor for severe disease.
The Use of Antiplatelet Agents and Heparin in the 24-Hour Postintravenous Alteplase Window for Neurointervention
Binning, Mandy J., Maxwell, Christina R. , McAree, Michael, Veznedaroglu, Erol, Wolfe, Stacey Q , Tschoe, Christine , Crowley, R. Webster , Vakharia, Kunal , Hamid, H , Ringer, Andrew J. , Liebman, Kenneth, Wolfe, Stacey Quintero , Felbaum, Daniel R. , Arthur, Adam Stephen , Goyal, Nitin , Levy, Elad I. , Pandey, Aditya S , Daou, Badih Junior , Tawk, Rabih G.

Mayo Clinic

Neurosurgery | November 13, 2020 | Volume: 88 | Issue: 4 | Pages: 746-750

10.1093/neuros/nyaa530 | PMID 33442725 Get It

Abstract BACKGROUND Intravenous (IV) alteplase with mechanical thrombectomy has been found to be superior to alteplase alone in select patients with intracranial large vessel occlusion. Current guidelines discourage the use of antiplatelet agents or heparin for 24 h following alteplase. However, their use is often necessary in certain circumstances during thrombectomy procedures. OBJECTIVE To study the safety and outcomes in patients who received blood thinning medications for thrombectomy after IV Tissue-Type plasminogen activator (tPA). METHODS This is a multicenter retrospective review of the use of antiplatelet agents and/or heparin in patients within 24 h following tPA administration. Patient demographics, comorbidities, bleeding complications, and discharge outcomes were collected. RESULTS A series of 88 patients at 9 centers received antiplatelet medications and/or heparin anticoagulation following IV alteplase for revascularization procedures requiring stenting. The mean National Institutes of Health Stroke Scale (NIHSS) on admission was 14.6. Reasons for use of a stent included internal carotid artery occlusion in 74% of patients. Thrombolysis in cerebral infarction (TICI) 2b-3 revascularization was accomplished in 90% of patients. The rate of symptomatic intracranial hemorrhage (sICH) was 8%; this was not significantly different than the sICH rate for a matched group of patients not receiving antiplatelets or heparin during the same time frame. Functional independence at 90 d (modified Rankin Scale 0-2) was seen in 57.8% of patients. All-cause mortality was 12%. CONCLUSION The use of antiplatelet agents and heparin for stroke interventions following IV alteplase appears to be safe without significant increased risk of hemorrhagic complications in this group of patients when compared to control data and randomized controlled trials.
A multi-institutional review of endovenous thermal ablation of the saphenous vein finds male sex and use of anticoagulation are predictors of long-term failure
Erben, Young , Vasquez, Isabel, Li, Yupeng , Gloviczki, Péter , Kalra, Manju , Martino, Randall R. De , Bjarnason, Haraldur , Neisen, Melissa , Moore, January , Rocha-Franco, Joao A. Da, Sanchez-Valenzuela, Maria C., Frey, G. , Toskich, Beau , Devcic, Zlatko , Farres, Houssam , Oldenburg, W. A., Gomez-Perez, Jessica, Yarbrough, Justin, Adalia, Michael, Stone, William M., Meltzer, Andrew J., Hakaim, Albert G., Oderich, Gustavo, De Martino, Randall R, Neisen, Melissa J, Moore, January F, Da Rocha-Franco, Joao A, Oldenburg, Warren A, Yarbrough, Justin R, Stone, William, Bjarnason, Haraldur , Oderich, Gustavo S. , Gloviczki, Péter

Mayo Clinic

Phlebology: The Journal of Venous Disease | November 12, 2020 | Volume: 36 | Issue: 4 | Pages: 283-289

10.1177/0268355520972923 | PMID 33176592 Get It

Background To review long-term outcomes and saphenous vein (SV) occlusion rate after endovenous ablation (EVA) for symptomatic varicose veins. Methods A review of our EVA database (1998–2018) with at least 3-years of clinical and sonographic follow-up. The primary end point was SV closure rate. Results 542 limbs were evaluated. 358 limbs had radiofrequency and 323 limbs had laser ablations; 542 great saphenous veins (GSV), 106 small saphenous veins (SSV) and 33 anterior accessory saphenous veins (AASV) were treated. Follow-up was 5.6 ± 2.3 years; 508 (74.6%) veins were occluded, 53 (7.8%) partially occluded and 120 (17.6%) were patent. On multivariable Cox regression analysis, male sex (HR 1.6, 95% CI [0.46–018], p = 0.012) and use anticoagulation (HR 2.0, 95% CI [0.69–0.34], p = 0.044) were predictors of long-term failure. On Kaplan-Meier curve, we had an 86.3% occlusion rate. Conclusion Our experience revealed a 5-year closure rate of 86.3%. Ablations have satisfactory occlusion rate.
Intraoperative Hypotension Is Associated With Adverse Clinical Outcomes After Noncardiac Surgery
Gregory, Anne, Stapelfeldt, Wolf H. , Boero, Isabel J., Chen, Qinyu , Stevens, Mitali, Smischney, Nathan J. , Khanna, Ashish K. , Shaw, Andrew

Mayo Clinic

Anesthesia & Analgesia | November 11, 2020 | Volume: 132 | Issue: 6 | Pages: 1654-1665

10.1213/ane.0000000000005250 | PMID 33177322 Get It

BACKGROUND: Intraoperative hypotension (IOH) occurs frequently during surgery and may be associated with organ ischemia; however, few multicenter studies report data regarding its associations with adverse postoperative outcomes across varying hemodynamic thresholds. Additionally, no study has evaluated the association between IOH exposure and adverse outcomes among patients by various age groups. METHODS: A multicenter retrospective cohort study was conducted between 2008 and 2017 using intraoperative blood pressure data from the US electronic health records database to examine postoperative outcomes. IOH was assessed in 368,222 noncardiac surgical procedures using 5 methods: (a) absolute maximum decrease in mean arterial pressure (MAP) during surgery, (b) time under each absolute threshold, (c) total area under each threshold, (d) time-weighted average MAP under each threshold, and (e) cumulative time under the prespecified relative MAP thresholds. MAP thresholds were defined by absolute limits (≤75, ≤65, ≤55 mm Hg) and by relative limits (20% and 40% lower than baseline). The primary outcome was major adverse cardiac or cerebrovascular events; secondary outcomes were all-cause 30- and 90-day mortality, 30-day acute myocardial injury, and 30-day acute ischemic stroke. Residual confounding was minimized by controlling for observable patient and surgical factors. In addition, we stratified patients into age subgroups (18–40, 41–50, 51–60, 61–70, 71–80, >80) to investigate how the association between hypotension and the likelihood of major adverse cardiac or cerebrovascular events and acute kidney injury differs in these age subgroups. RESULTS: IOH was common with at least 1 reading of MAP ≤75 mm Hg occurring in 39.5% (145,743) of cases; ≤65 mm Hg in 19.3% (70,938) of cases, and ≤55 mm Hg in 7.5% (27,473) of cases. IOH was significantly associated with the primary outcome for all age groups. For an absolute maximum decrease, the estimated odds of a major adverse cardiac or cerebrovascular events in the 30-day postsurgery was increased by 12% (95% confidence interval [CI], 11-14) for ≤75 mm Hg; 17.0% (95% CI, 15-19) for ≤65 mm Hg; and by 26.0% (95% CI, 22-29) for ≤55 mm Hg. CONCLUSIONS: IOH during noncardiac surgery is common and associated with increased 30-day major adverse cardiac or cerebrovascular events. This observation is magnified with increasing hypotension severity. The potentially avoidable nature of the hazard, and the extent of the exposed population, makes hypotension in the operating room a serious public health issue that should not be ignored for any age group.
Consensus Statement for the Management and Treatment of Port-Wine Birthmarks in Sturge-Weber Syndrome
Sabeti, Sara , Ball, Karen L. , Burkhart, Craig N. , Eichenfield, Lawrence F. , Frieden, Ilona J. , Geronemus, Roy G. , Gupta, Deepti , Krakowski, Andrew C. , Levy, Moise L. , Metry, Denise W. , Nelson, J. Stuart , Tollefson, Megha M. , Kelly, Kristen M. , Kelly, Kristen M , Sabeti, Sara, Faith, Esteban Fernández

Mayo Clinic

JAMA Dermatology | November 11, 2020 | Volume: 157 | Issue: 1 | Pages: 98

10.1001/jamadermatol.2020.4226 | PMID 33175124 Get It

Mesangial expansion at 5 years predicts death and death‐censored graft loss after renal transplantation
Kukla, Aleksandra , Alexander, Mariam P., Túrkevi-Nagy, Sándor , Merzkani, Massini , Smith, Byron H. , Zhang, Pingchuan , Benavides, Xiomara , D’Costa, Matthew R. , Alvarez, Catalina , Đenić, Aleksandar , Bentall, Andrew , Kudva, Yogish C. , Stegall, Mark D. , Park, Walter, Smith, Byron , Zhang, Pingchuan , D'Costa, Matthew , Morales Alvarez, Catalina, Denic, Aleksandar , Bentall, Andrew , Kudva, Yogish C. , Stegall, Mark D , Park, Walter D.

Mayo Clinic

Clinical Transplantation | November 10, 2020 | Volume: 35 | Issue: 1 | Pages: No page available

10.1111/ctr.14147 | PMID 33170556 Get It

AbstractDeath with a functioning graft and death‐censored renal allograft failure remain major problems for which effective preventative protocols are lacking. The retrospective cohort study aimed to determine whether histologic changes on a 5‐year surveillance kidney biopsy predict adverse outcomes after transplantation in recipients who had: both Type 2 diabetes (T2DM) and obesity (BMI ≥ 30 kg/m2) at the time of transplantation (T2DM/Obesity, n = 75); neither (No T2DM/No obesity, n = 78); No T2DM/Obesity (n = 41), and T2DM/No obesity (n = 47). On 5‐year biopsies, moderate‐to‐severe mesangial expansion was more common in the T2DM/Obesity group (Banff mm score ≥2 = 49.3%; Tervaert classification MS ≥ 2b = 26.7%) compared to the other groups (p < .001 for both scores). Risk factors included older age, higher BMI, HbA1C, and triglycerides at 1‐year post‐transplant. Moderate‐to‐severe mesangial expansion correlated with death with function (HR 1.74 (1.01, 2.98), p = .045 Banff and 1.89 (1.01, 3.51) p = .045 Tervaert) and with death‐censored graft loss (HR 3.2 (1.2, 8.8), p = .02 Banff and HR 3.8 (1.3, 11.5), p = .01 Tervaert) over a mean of 11.6 years of recipient follow‐up post‐transplant. These data suggest that mesangial expansion in recipients with T2DM and obesity may reflect systemic vascular injury and might be a novel biomarker to predict adverse outcomes post renal transplant.
Dopamine D1 receptor stimulates cathepsin K-dependent degradation and resorption of collagen I in lung fibroblasts
Espinosa, Ana M. Diaz , Link, Patrick A. , Sicard, Delphine , Jorba, Ignasi , Tschumperlin, Daniel J. , Haak, Andrew J. , Diaz-Espinosa, Ana M, Diaz Espinosa, Ana M , Link, Patrick A

Mayo Clinic

Journal of Cell Science | November 10, 2020 | Volume: 133 | Issue: 23 | Pages: No page available

10.1242/jcs.248278 | PMID 33172983 Get It

ABSTRACT Matrix resorption is essential to the clearance of the extracellular matrix (ECM) after normal wound healing. A disruption in these processes constitutes a main component of fibrotic diseases, characterized by excess deposition and diminished clearance of fibrillar ECM proteins, such as collagen type I. The mechanisms and stimuli regulating ECM resorption in the lung remain poorly understood. Recently, agonism of dopamine receptor D1 (DRD1), which is predominantly expressed on fibroblasts in the lung, has been shown to accelerate tissue repair and clearance of ECM following bleomycin injury in mice. Therefore, we investigated whether DRD1 receptor signaling promotes the degradation of collagen type I by lung fibroblasts. For cultured fibroblasts, we found that DRD1 agonism enhances extracellular cleavage, internalization and lysosomal degradation of collagen I mediated by cathepsin K, which results in reduced stiffness of cell-derived matrices, as measured by atomic force microscopy. In vivo agonism of DRD1 similarly enhanced fibrillar collagen degradation by fibroblasts, as assessed by tissue labeling with a collagen-hybridizing peptide. Together, these results implicate DRD1 agonism in fibroblast-mediated collagen clearance, suggesting an important role for this mechanism in fibrosis resolution. This article has an associated First Person interview with the first author of the paper.
Healthcare Worker With Large Vessel Acute Ischemic Stroke Likely Related to Mild SARS-CoV-2 Infection
Castillo, Carlos , Lamotte, Guillaume , Mehta, Amit , Sonti, Rajiv , Maria, Gianluca Di, Ruiz, Daniel Carnevali , Kumar, Princy , Stemer, Andrew B., Denny, Mary Carter , Castillo-Pinto, Carlos , Denny, M Carter , Mehta, Amit , Lamotte, Guillaume

Mayo Clinic

The Neurohospitalist | November 10, 2020 | Volume: 12 | Issue: 1 | Pages: 48-56

10.1177/1941874420966845 | PMID 34950386 Get It

We report the case of a healthcare worker who presented with a large vessel acute ischemic stroke in setting of a mild SARS-CoV-2 infection and provide a review of the emerging literature on COVID-related stroke. A 43-year-old female presented with right-sided hemiparesis, aphasia and dysarthria. She had a nonproductive of cough for 1 week without fever, fatigue or dyspnea. A CT Head, CT angiography and CT perfusion imaging revealed a M1 segment occlusion of the left middle cerebral artery requiring transfer from a primary to a comprehensive stroke center. A nasopharyngeal swab confirmed SARS-CoV-2 infection prior to arrival at the accepting center. During the thrombectomy a 3 cm thrombus was removed. Thrombus was also evident in the 8 French short sheath during closure device placement so a hypercoagulable state was suspected. Stroke work-up revealed a glycosylated hemoglobin of 8.7%, elevation of inflammatory markers and an indeterminate level of lupus anticoagulant IgM. On discharge home, she had near complete neurological recovery. This case highlights suspected mechanisms of hypercoagulability in SARS-CoV-2 infection and the importance of optimizing stroke care systems during the COVID-19 pandemic.